Introduction
cardiovascular disease, AD-related cognitive decline, cognitive impairment, cognitive decline/dementia, Alzheimer’s disease, cognitive decline, AD
PVC, PATHOLOGY, CARDIOVASCULAR DISEASE, BRAIN
Accurate measurement of Alzheimer’s disease (AD) pathology in older adults without significant clinical impairment is critical to assessing intervention strategies aimed at slowing AD-related cognitive decline. The U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (POINTER) is a 2-year randomized controlled trial to evaluate the effect of multicomponent risk reduction strategies in older adults (60-79 years) who are cognitively unimpaired but at increased risk for cognitive decline/dementia due to factors such as cardiovascular disease and family history. The POINTER Imaging ancillary study is collecting tau-PET ([Quantification of early pathological tau in individuals without significant cognitive impairment is essential to uncovering the mechanisms by which Alzheimer’s disease (AD) pathology leads to cognitive decline (Across several tracers, tau-PET OTS has been shown to be related to factors associated with AD incidence and progression including age, sex and race (MK6240 is a second-generation tau-PET tracer with several advantages over first-generation tracers, including minimal OTS in the basal ganglia and choroid plexus and a higher dynamic range, especially in individuals with AD with more advanced tau pathology (In the present study, we had two main aims. The first aim was to characterize MK6240 meningeal OTS in a large cross-sectional cohort of older adults from the POINTER Imaging ancillary study. This included describing key problems arising from meningeal signal and exploring the biological drivers of meningeal binding. Specifically, we test whether age, sex or race is related to the magnitude of OTS in the meninges. Second, we explored various processing approaches, including partial volume correction (PVC) (